The headline has been corrected to state that Biocept's first quarter revenues decreased, not increased, 20 percent.

NEW YORK (GenomeWeb) – Newly publicly traded firm Biocept yesterday reported a 20 percent drop year over year in its first quarter revenues.

In a Form 10-Q filed with the US Securities and Exchange Commission, the San Diego-based firm said that revenues shrank to $28,275 for the three months ended March 31, compared to $35,154 in the year-ago quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.